Welcome to our dedicated page for Spyre Therapeutics SEC filings (Ticker: SYRE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Investors trying to untangle Spyre Therapeutics’ biotech disclosures often wade through pages of immunology jargon, multi-year R&D accruals, and milestone-based licensing clauses. Locating clinical-trial costs in a 10-K or confirming a sudden Form 8-K study halt can take hours, and tracking executive share sales before financing rounds is even harder. That complexity is why so many searches start with natural questions like “where can I find Spyre Therapeutics quarterly earnings report 10-Q filing?” or “Spyre Therapeutics insider trading Form 4 transactions.” We built this page to answer those questions immediately.
With Stock Titan’s AI-powered analysis, every Spyre Therapeutics SEC filing is explained simply. Our algorithms parse the latest 10-K annual report, highlight key pipeline disclosures, and surface cash-burn trends, giving you a “Spyre Therapeutics annual report 10-K simplified” view in seconds. Real-time alerts flag “Spyre Therapeutics Form 4 insider transactions” the moment they hit EDGAR, while concise summaries break down each “Spyre Therapeutics 8-K material events explained” notice. Whether you need “Spyre Therapeutics proxy statement executive compensation” tables, or an “earnings report filing analysis” of quarterly R&D spend, the information arrives ready to use.
Every filing is linked to what matters for this clinical-stage IBD innovator. Compare α4β7 antibody trial results across quarters, monitor financing covenants that could shift run-way projections, or study “understanding Spyre Therapeutics SEC documents with AI” case notes that connect pipeline milestones to market valuation. Our coverage spans all forms—10-K, 10-Q, 8-K, S-1, and the executive stock transactions Form 4 feed—updated in real time. Spend less time decoding dense biology and more time making informed decisions with complete, investor-ready context.
Spyre Therapeutics (SYRE) completed an underwritten public offering of common stock. The company sold 14,864,865 shares at $18.50 per share and granted a 30-day option for up to 2,229,729 additional shares, which the underwriters exercised in full on October 14, 2025. The offering closed on October 15, 2025.
Gross proceeds were approximately $316.2 million before underwriting discounts, commissions, and expenses. Spyre plans to use the net proceeds to advance its inflammatory bowel disease and rheumatic disease programs, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, as well as for working capital and general corporate purposes. The transaction was conducted off an effective Form S-3 shelf, with Jefferies, TD Securities (USA), Leerink Partners, and Stifel as representatives of the underwriters.
Spyre Therapeutics (SYRE) is offering 14,864,865 shares of common stock at $18.50 per share. The deal implies $275,000,002 in gross proceeds, underwriting discounts of $16,500,000, and estimated net proceeds of about $257.7 million after expenses. Underwriters have a 30‑day option to purchase up to 2,229,729 additional shares.
The company plans to use proceeds to advance programs in inflammatory bowel disease and rheumatic diseases, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, plus working capital and general corporate purposes. Shares trade on Nasdaq as SYRE; the last reported price was $18.92 on October 13, 2025. Delivery of shares is expected on or about October 15, 2025.
The filing highlights dilution to new investors of $9.02 per share based on the pro forma as‑adjusted net tangible book value analysis. As context, the company preliminarily reported $486.2 million in cash, cash equivalents and marketable securities as of September 30, 2025.
Spyre Therapeutics (SYRE) launched a primary offering of common stock and, in lieu of shares for certain investors, pre-funded warrants under its effective Form S-3 shelf. The company will receive the proceeds and has also granted underwriters an option to purchase additional shares within 30 days. The pre-funded warrants have a $0.0001 per-share exercise price and include beneficial ownership limits.
Spyre plans to use proceeds to advance its IBD and rheumatic disease programs, including preclinical work, clinical trials, manufacturing, and Phase 3 readiness, as well as for working capital and general corporate purposes. The company reported preliminary cash, cash equivalents and marketable securities of $486.2 million as of September 30, 2025. SYRE trades on Nasdaq; the pre-funded warrants will not be listed.
Spyre Therapeutics announced it expects to report approximately $486.2 million in cash, cash equivalents and marketable securities as of September 30, 2025.
The figure is preliminary, has not been audited, and remains subject to completion of financial closing procedures. The company’s independent registered public accounting firm has not audited, reviewed, or performed procedures on this information and does not express assurance. The disclosure was provided under Item 2.02 of an 8-K and is furnished, not filed.
Spyre Therapeutics CFO Scott L. Burrows reported a sell-to-cover transaction tied to the settlement of restricted stock units. The filing shows 18,428 shares of common stock were sold at a weighted average price reported near $16.26, generated to satisfy tax withholding obligations arising from the settlement of 33,738 RSUs. Following the sale, the reporting person beneficially owns 97,994 shares outright.
The report also discloses an additional 67,476 RSUs that remain outstanding; those RSUs vest in two equal installments on September 1, 2026 and September 1, 2027, subject to continued employment. The transaction is described as non-discretionary and solely for tax withholding.
FAQ
What is the current stock price of Spyre Therapeutics (SYRE)?
What is the market cap of Spyre Therapeutics (SYRE)?
